Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.38 |
| ▸ | APP | P05067 | 2/20 | 0.37 |
| ▸ | ESRRG | P62508 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 6/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23134884 | 0.88 | APP (0.40) | MAPTAPPESRRGMEN1KMT2A | |
| SCHEMBL18220271 | 0.88 | MAPT (0.36) | MAPTAPPESRRGMEN1KMT2A | |
| SCHEMBL18220159 | 0.87 | MAPT (0.37) | MAPTAPPESRRGMEN1KMT2A | |
| SCHEMBL17120673 | 0.87 | MAPT (0.35) | MAPTAPP | |
| SCHEMBL19294125 | 0.87 | MAPT (0.36) | MAPTAPPMEN1KMT2AALDH1A1 | |
| SCHEMBL18221576 | 0.83 | MAPT (0.33) | MAPTAPP | |
| SCHEMBL23135076 | 0.83 | APP (0.33) | MAPTAPPMEN1KMT2AALDH1A1 | |
| SCHEMBL18220308 | 0.82 | MAPT (0.32) | MAPTAPP | |
| SCHEMBL17120795 | 0.82 | MAPT (0.48) | MAPTAPPESRRGMEN1KMT2A | |
| SCHEMBL18220423 | 0.81 | MAPT (0.31) | MAPTAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005745-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005745-B2 | Amyloid targeting agents and methods of using the same | APP, APBA1, CRYAA | MAPT 26/4885APP 1/4885ESRRG 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.